{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:13:31Z","timestamp":1778314411051,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.antiviral.2018.01.013","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T16:40:17Z","timestamp":1517503217000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors"],"prefix":"10.1016","volume":"152","author":[{"given":"Tomokazu","family":"Yoshinaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Suyama-Kagitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Kawauchi-Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-1679","authenticated-orcid":false,"given":"Akihiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamio","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.01.013_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/JVI.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J. Virol."},{"issue":"36","key":"10.1016\/j.antiviral.2018.01.013_bib2","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2018.01.013_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077448","article-title":"Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics","volume":"8","author":"DeAnda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.013_bib4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/AAC.01218-07","article-title":"The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral","volume":"52","author":"Garvey","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.01.013_bib5","doi-asserted-by":"crossref","first-page":"8892","DOI":"10.1021\/bi9907173","article-title":"The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity","volume":"38","author":"Greenwald","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.01.013_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.2992081","article-title":"Infection of HTLV-III\/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay","volume":"229","author":"Harada","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.01.013_bib7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature08784","article-title":"Retroviral intasome assembly and inhibition of DNA strand transfer","volume":"464","author":"Hare","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.01.013_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/viro.1999.0006","article-title":"Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5","volume":"264","author":"Isaka","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.01.013_bib9","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/jm400645w","article-title":"Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S\/GSK1349572) and (S\/GSK1265744)","volume":"56","author":"Johns","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.01.013_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.01.013_bib11","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/jac\/dkt012","article-title":"Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors","volume":"68","author":"Koning","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.01.013_bib12","first-page":"15910","article-title":"Structure-based modeling of the functional HIV-1 intasome and its inhibition","volume":"107","author":"Krishnan","year":"2010"},{"key":"10.1016\/j.antiviral.2018.01.013_bib13","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/jac\/dkr389","article-title":"The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype","volume":"66","author":"Malet","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.01.013_bib14","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","article-title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","volume":"15","author":"Margolis","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.013_bib15","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.01.013_bib16","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","volume":"4","author":"Markowitz","year":"2017","journal-title":"Lancet. HIV"},{"key":"10.1016\/j.antiviral.2018.01.013_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.antiviral.2008.10.007","article-title":"Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics","volume":"81","author":"Nakahara","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.01.013_bib18","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1128\/AAC.04844-14","article-title":"Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro","volume":"59","author":"Seki","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.01.013_bib19","series-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV","author":"U.S. Department of Health & Human Services","year":"2017"},{"key":"10.1016\/j.antiviral.2018.01.013_bib20","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/AAC.01791-12","article-title":"Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S\/GSK1349572)","volume":"57","author":"Vavro","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.01.013_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1128\/AAC.03909-14","article-title":"Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection","volume":"59","author":"Yoshinaga","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.01.013_bib22","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1128\/JVI.78.10.5045-5055.2004","article-title":"Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase","volume":"78","author":"Zhu","year":"2004","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217306848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217306848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T23:18:59Z","timestamp":1603754339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217306848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":22,"alternative-id":["S0166354217306848"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.01.013","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}